F. Naso et al. / Tetrahedron: Asymmetry 17 (2006) 3226–3229
3229
yield, 69–80% ee),22 under analogous reaction conditions
(0 °C, 2 h reaction time). Thus, Sulindac sulfide alkyl
esters, that is, large molecules bearing various functional
groups, behaved similarly to small aryl methyl sulfides.
2. Jung, M.; Wahl, A. F.; Neupert, W.; Geisslinger, G.; Senter,
P. D. Pharm. Pharmacol. Commun. 2000, 6, 217–221.
3. Duffy, C. P.; Elliott, C. J.; O’ Connor, R. A.; Heenan, M. M.;
Coyle, S.; Cleary, I. M.; Kavanagh, K.; Verhaegen, S.; O’
Loughlin, C. M.; NicAmhlaoibh, R.; Clynes, M. Eur. J.
Cancer 1998, 34, 1250–1259.
4. Piazza, G. A.; Kulchak Rahm, A. L.; Krutzsch, M.; Sperl, G.;
Paranka, N. S.; Gross, P. H.; Brendel, K.; Burt, R. W.;
Alberts, D. S.; Pamucku, R.; Ahnen, D. J. Cancer Res. 1995,
55, 3110–3116.
5. Jung, B.; Barbier, V.; Brickner, H.; Welsh, J.; Fotedar, A.;
McClelland, M. Cancer Lett. 2005, 219, 15–25.
6. Baldwin, G. S.; Rorison, K. A. Biochim. Biophys. Acta 1999,
1428, 68–76.
7. Maguire, A. R.; Papot, S.; Ford, A.; Touhey, S.; O’ Connor,
R.; Clynes, M. Synlett 2001, 41–44.
Furthermore, from the present and past investigations, the
mechanism of the asymmetric oxidation of sulfides in the
presence of a complex between titanium and hydrobenzoin
seems to be substrate sensitive. In the first case, a genuine
enantioselective oxidation occurs, as observed in the prep-
aration of aryl benzyl sulfoxides14 or aryl b-ketosul-
foxides.15 High ee values and high yields, due to the
presence of only negligible amounts of the corresponding
sulfone, are obtained. Thus, it is useless to perform the
reaction at 0 °C, or with a short reaction time, since the
over-oxidation of the sulfoxide is marginal, even at longer
reaction times. On the other hand, enantioselective oxida-
tion of the alkyl aryl sulfide (simple, as aryl methyl sulfide22
or complex, as Sulindac sulfide alkyl esters) follows a two-
step mechanism (enantioselective oxidation/kinetic resolu-
tion). Better ee values require that the presence of the
sulfone has to be accepted, together with a consequent
decrease of the isolated yields of the target optically active
sulfoxide.
8. Korte, A.; Legros, J.; Bolm, C. Synlett 2004, 2397–2399.
9. Light, D. R.; Waxman, D. J.; Walsh, C. Biochemistry 1982,
21, 2490–2498.
10. Hamman, M. A.; Haehner-Daniels, B. D.; Wrighton, S. A.;
Rettie, A. E.; Hall, S. D. Biochem. Pharmacol. 2000, 60, 7–17.
11. Bolm, C.; Muniz, K.; Hildebrand, J. P. Oxidations of
˜
Sulfides. In Comprehensive Asymmetric Catalysis; Jacobsen,
E. N., Pfalz, A., Yamamoto, H., Eds.; Springer: Berlin, 1999;
pp 697–710.
12. Legros, J.; Dehli, J. R.; Bolm, C. Adv. Synth. Catal. 2005,
347, 19–31.
13. Capozzi, M. A. M.; Cardellicchio, C.; Naso, F. Eur. J. Org.
Chem. 2004, 1855–1863.
14. Capozzi, M. A. M.; Cardellicchio, C.; Naso, F.; Rosito, V. J.
Org. Chem. 2002, 67, 7289–7294.
15. Cardellicchio, C.; Hassan Omar, O.; Naso, F.; Capozzi, M.
A. M.; Capitelli, F.; Bertolasi, V. Tetrahedron: Asymmetry
2006, 17, 223–229.
Even if more work on this topic seems to be needed, the
mechanistic observations collected herein depicted a preli-
minary reactivity framework that should be useful in future
application of this oxidation system to the synthesis of
other bioactive chiral sulfoxides.
16. Seto, M.; Miyamoto, N.; Aikawa, K.; Aramaki, Y.; Kanzai,
N.; Iizawa, Y.; Baba, M.; Shiraishi, M. Bioorg. Med. Chem.
2005, 13, 363–386.
Acknowledgements
17. Meneghin, M. European Patent EP0206241, 1986.
18. Sperl, G.; Gross, P.; Pamucku, R.; Brendel, K.; Piazza, G. A.
U.S. Patent 6,071,934, 2000.
19. Drago, C.; Caggiano, L.; Jackson, R. F. W. Angew. Chem.,
Int. Ed. 2005, 44, 7221–7223.
20. Kelly, P.; Lawrence, S. E.; Maguire, A. R. Synlett 2006,
1569–1573.
21. Kelly, P.; Lawrence, S. E.; Maguire, A. R. Eur. J. Org. Chem.
2006, 4500–4509.
22. Donnoli, M. I.; Superchi, S.; Rosini, C. J. Org. Chem. 1998,
63, 9392–9395.
23. Jia, X.; Li, X.; Xu, L.; Li, Y.; Shi, Q.; Au-Yeung, T. T.-L.;
Yip, C. W.; Yao, X.; Chan, A. S. C. Adv. Synth. Catal. 2004,
346, 723–726.
This work was financially supported, in part, by the MIUR
Rome (National Project ‘Stereoselezione in Sintesi Orga-
nica. Metodologie e Applicazioni’), by the FIRB project
(‘Progettazione, preparazione e valutazione biologica e far-
macologica di nuove molecole organiche quali potenziali
farmaci innovativi’) and by the Ministero della Salute-
Regione Puglia project (‘Farmacoprevenzione nei pazienti
con mieloma multiplo. Inibizione dell’angiogenesi e della
crescita tumorale con inibitori della COX-2’). Thanks are
due to Dr. Nicola Caldarola for preliminary works.
24. Hinkley, D.; Conn, J. U.S. Patent 3,732,292, 1973; Chem-
erda, J. M.; Pines, S. H. Swiss Patent CH 615418, 1980.
25. Buist, P. H.; Marecak, D.; Holland, H. L.; Brown, F. M.
Tetrahedron: Asymmetry 1995, 6, 7–11.
References
1. Jones, H. U.S. Patent 3,869,507, 1975; Jones, H. U.S. Patent
3,868,415, 1975.